|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| COVID-19 vaccination logo  As of 14 November 2024 | **Pfizer (COMIRNATY) JN.1**  **6 months – 4 years**  3 mcg/0.3 mL  concentrated suspension for injection multi-dose vial | **Pfizer (COMIRNATY) JN.1**  **5 – 11 years**  10 mcg/0.3 mL  suspension for injection  single-dose vial | **Pfizer (COMIRNATY) JN.1**  **12 years+**  30 mcg/0.3 mL  suspension for injection  multi-dose vial | **Pfizer (COMIRNATY) JN.1**  **12 years+**  30 mcg/0.3 mL  suspension for injection  single-dose glass prefilled syringes | **Pfizer (COMIRNATY) Omicron XBB.1.5**  **6 months – 4 years**  3 mcg/0.2 mL  concentrated suspension for injection multi-dose vial | **Pfizer (COMIRNATY) Omicron XBB.1.5**  **5 – 11 years**  10 mcg/0.3 mL  suspension for injection  single-dose vial | **Pfizer (COMIRNATY) Omicron XBB.1.5**  **12 years+**  30 mcg/0.3 mL  suspension for injection  multi-dose vial |
|  |  |  |  |  |  |  |  |
| CVAS naming convention | Pfizer (JN.1) 6 months – 4 years (Yellow) | Pfizer (JN.1) 5 – 11 years  (Light Blue) | Pfizer (JN.1) 12 years+  (Dark Grey) | Pfizer (JN.1) 12 years+  (PFS) | Pfizer (XBB.1.5) 6 months - 4 years (Maroon) | Pfizer (XBB.1.5) 5 - 11 years (Light Blue) | Pfizer (XBB.1.5) 12 years+ (Grey) |
| Vaccine type | mRNA (nucleic acid) | mRNA (nucleic acid) | mRNA (nucleic acid) | mRNA (nucleic acid) | mRNA (nucleic acid) | mRNA (nucleic acid) | mRNA (nucleic acid) |
| Approved age | 6 months – 4 years | 5 – 11 years | 12 years and older | 12 years and older | 6 months to 4 years | 5 to 11 years | 12 years and older |
| Dose volume | 0.3 mL | 0.3 mL | 0.3 mL | 0.3mL | 0.2 mL | 0.3 mL | 0.3 mL |
| Doses per vial | 3 | 1 | 6 | 1 | 10 | 1 | 6 |
| Dilution required | Yes (1.1 mL) | No | No | No | Yes (2.2 mL) | No | No |
| ULT freezer storage time | 18 months (shelf life) at  -90°C to -60°C | 18 months (shelf life) at  -90°C to -60°C | 18 months (shelf life) at  -90°C to -60°C | NA | 24 months (shelf life) at  -90°C to -60°C | 24 months (shelf life) at  -90°C to -60°C | 24 months (shelf life) at  -90°C to -60°C |
| Freezer storage time (unopened) | DO NOT STORE at  -25°C to -15°C | DO NOT STORE at  -25°C to -15°C | DO NOT STORE at  -25°C to -15°C | DO NOT FREEZE | DO NOT STORE at  -25°C to -15°C | DO NOT STORE at  -25°C to -15°C | DO NOT STORE at  -25°C to -15°C |
| Refrigeration storage time (unopened)1 | 70 days (+2°C to +8°C) within the 18-month shelf life | 70 days (+2°C to +8°C) within the 18-month shelf life | 70 days (+2°C to +8°C) within the 18-month shelf life | Expiry date printed on the carton and syringe label | 70 days (+2°C to +8°C) within the 24-month shelf life | 70 days (+2°C to +8°C) within the 24-month shelf life | 70 days (+2°C to +8°C) within the 24-month shelf life |
| Room temperature storage time (unopened) | 24 hours pre- and post- dilution (up to +30°C) | 24 hours pre- and post-initial puncture (up to +30°C) | 24 hours pre- and post-initial puncture (up to +30°C) | 12 hours (up to +30°C) | 24 hours pre- and post-dilution (up to +30°C) | 24 hours pre- and post-initial puncture (up to +30°C) | 24 hours pre- and post-initial puncture (up to +30°C) |
| Storing opened vials | 6 hours (up to +30°C) | 6 hours (up to +30°C) | 6 hours (up to +30°C) | NA | 6 hours (up to +30°C) | 6 hours (up to +30°C) | 6 hours (up to +30°C) |
| Storing pre-drawn doses | 1 hour (up to +30°C) or 6 hours (+2°C to +8°C) | 1 hour (up to +30°C) or 6 hours (+2°C to +8°C) | 1 hour (up to +30°C) or 6 hours (+2°C to +8°C) | NA | 1 hour (up to +30°C) or 6 hours (+2°C to +8°C) | 1 hour (up to +30°C) or 6 hours (+2°C to +8°C) | 1 hour (up to +30°C) or 6 hours (+2°C to +8°C) |
| TGA Product Information (PI) and Consumer Medicine Information (CMI) | [PI](https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2024-PI-02704-1&d=20241030172310101)  [CMI](https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2024-CMI-02705-1) | [PI](https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2024-PI-02704-1&d=20241030172310101)  [CMI](https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2024-CMI-02705-1) | [PI](https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2024-PI-02704-1&d=20241030172310101)  [CMI](https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2024-CMI-02705-1) | [PI](https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2024-PI-02704-1&d=20241030172310101)  [CMI](https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2024-CMI-02705-1) | [PI](https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2023-PI-02409-1&d=202104131016933&d=20231011172310101&d=20231016172310101&d=20231122172310101&d=20240312172310101)  [CMI](https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2023-CMI-02414-1) | [PI](https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2023-PI-02409-1&d=202104131016933&d=20231011172310101&d=20231016172310101&d=20231122172310101&d=20240312172310101)  [CMI](https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2023-CMI-02414-1) | [PI](https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2023-PI-02409-1&d=202104131016933&d=20231011172310101&d=20231016172310101&d=20231122172310101&d=20240312172310101)  [CMI](https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2023-CMI-02414-1) |
| **Notes:**  For the latest information on COVID-19 primary course and additional doses advise, please refer to the [Australian Immunisation Handbook](https://immunisationhandbook.health.gov.au/contents/vaccine-preventable-diseases/covid-19#recommendations):   * All adults aged 18 years and over are **recommended** a **single primary dose**. Children and adolescents aged under 18 years are not routinely recommended a primary dose. * People with severe immunocompromise conditions, who are over 6 months of age or older are recommended 2 primary doses and are eligible for a 3rd primary dose based on an individual risk-benefit assessment. * Infants, children and adolescents aged 6 months to <18 years with conditions other than severe immunocompromise that may increase the risk of severe COVID-19 are **eligible** for primary dose(s) based on a risk benefit assessment.   If vaccines are stored or handled outside the conditions listed, complete the Cold Chain Breach (CCB) reporting form and email it to the Vaccine Operations Centre (VOC) [COVID19VaccineOperationsCentre@health.gov.au](mailto:COVID19VaccineOperationsCentre@health.gov.au).  It is mandatory under the *Australian Immunisation Register Act 2015* for vaccination providers to report all vaccinations administered in Australia to the AIR. For more information, please visit [Advice for COVID-19 vaccine providers and administrators](https://www.health.gov.au/our-work/covid-19-vaccines/advice-for-providers).  Images © 2024 Pfizer Inc. All rights reserved. | | | | | | | |